Clinical

Dataset Information

0

Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer

ABSTRACT: This study is a retrospective study to compare the efficacy and safety between trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) with TAS-102 monotherapy in refractory metastatic colorectal cancer (mCRC) from November 2020 to October 2022 at the Hunan Cancer Hospital.

DISEASE(S): Metastatic Colorectal Adenocarcinoma,Colorectal Neoplasms

PROVIDER: 60837 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Biomarkers of Trifluridine-Tipiracil Efficacy.
| S-EPMC8658167 | biostudies-literature
Clinical Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer
| 2406756 | ecrin-mdr-crc
Transcriptomics single cell RNA-Seq of Dugesia japonica
2023-09-30 | GSE223927 | GEO
Clinical Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC
| 2398166 | ecrin-mdr-crc
Clinical Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia
| 2152626 | ecrin-mdr-crc
Unknown Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication.
| S-EPMC5717244 | biostudies-literature
Clinical Trifluridine/tipiracil(TAS-102)-induced nausea and vomiting in patients with colorectal cancer: a prospective, observational, multicenter study
| 2653963 | ecrin-mdr-crc
Other 190325_TX_CU18_MCSMAC_MeOH_H20_FA
2019-03-25 | MSV000083631 | MassIVE
Unknown Emerging combination therapies for metastatic colorectal cancer - impact of trifluridine/tipiracil.
| S-EPMC5635852 | biostudies-literature
Transcriptomics Seasonal bud dormancy progression
2007-08-24 | GSE8849 | GEO